ARQT News and Press, Arcutis Biotherapeutics Inc. From 08/03/22

Arcutis Biotherapeutics ( NASDAQ: ARQT ) jumps 6.5% after-hours Tuesday on pricing its underwritten public offering of 7.5M shares of its common stock at a public offering price of $20.00/share, representing a premium to the closing price of $19.50/share on August 2, 2022. ...

WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its unde...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) shares popped ~6% during extended trading on Tuesday after the biopharmaceutical company proposed a public offering of $150M of shares of its common stock. Arcutis ( ARQT ) intends to grant the underwriters a 30-day option t...

WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host a conference call for investors today at 8:30 a...

The U.S. FDA has approved Arcutis Biotherapeutics' ( NASDAQ: ARQT ) Zoryve (roflumilast) cream for plaque psoriasis in those 12 years old and up. The stock is up 6.5% in after-hours trading. The once-daily treatment is the first topical PDE4 inhibitor approved....

First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque psoriasis with no limitations on duration of use Established efficacy – ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks bottomed in mid-June and have seen some upward momentum since then. The recovery is in line with the broader market. But the industry has yet to get a lift from fundamental improvement. Click to Enlarge ...

Arcutis Biotherapeutics' ( NASDAQ: ARQT ) Canadian unit on Monday said the country's drug regulator had accepted its new drug submission (NDS) for its plaque psoriasis skin cream. Health Canada accepted Arcutis Canada's NDS for roflumilast cream 0.3% for the treatment ...

Arcutis Biotherapeutics Reaches Regulatory Milestone with Health Canada Acceptance of New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis Canada NewsWire Submission supported by efficacy data from the pivotal Phase 3 DERMIS-1 an...